查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1607976

骨髓惡性腫瘤檢測市場：按產品類型、技術、疾病類型、最終用戶分類 - 全球預測 2025-2030

Hematologic Malignancies Testing Market by Product (Consumables, Services, Testing Kits), Technology (Fluorescence In Situ Hybridization, Immunohistochemistry, Next-Generation Sequencing), Disease Type, End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

骨髓惡性腫瘤檢測市場2023年估值為33.5億美元，預計2024年將達36億美元，複合年成長率為7.82%，到2030年將達56.9億美元。

骨髓惡性腫瘤檢測的範圍包括一套旨在識別和表徵血癌的診斷和監測工具，包括白血病、淋巴瘤和骨髓瘤。這些測試對於確定特定的癌症類型、評估疾病進展和製定個人化治療計劃至關重要，因此對醫療保健提供者和患者都至關重要。市場應用涵蓋臨床診斷、研究和個人化醫療，最終用戶主要是醫院、實驗室和研究機構。推動市場成長要素是血癌盛行率的增加以及基因和分子檢測技術的進步。此外，對個人化醫療和早期疾病檢測的日益關注也推動了對這些測試的需求。最近的技術進步，例如次世代定序和基於 PCR 的方法，為滿足對精確和快速診斷不斷成長的需求提供了潛在的機會。希望利用這些機會的公司應該透過投資研發來提高測試準確性並降低成本，從而提高可及性。然而，先進測試設備的高成本、監管障礙以及對專業人員的需求等限制因素對市場成長構成了挑戰。此外，新興市場的醫療基礎設施和准入方面的差異進一步阻礙了採用。該領域的創新可能來自開發更具成本效益和攜帶式測試解決方案、增強照護現場診斷以及整合人工智慧和機器學習以更好地解釋資料。該市場不斷發展的性質反映在其對連接技術進步和臨床應用的承諾上。為了保持競爭力，企業應專注於分子診斷、基因檢測和生物感測器方面的策略聯盟和持續創新，以滿足癌症診斷準確性和效率的需求。

主要市場統計
基準年[2023] 33.5億美元
預測年份 [2024] 36億美元
預測年份 [2030] 56.9億美元
複合年成長率（%） 7.82%

市場動態：快速發展的骨髓惡性腫瘤檢測市場的關鍵市場洞察

供需的動態交互作用正在改變骨髓惡性腫瘤檢測市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 人口老化和骨髓惡性腫瘤增加
    • 傾向早期診斷和早期治療
    • 採用免疫療法和標靶藥物
  • 市場限制因素
    • 骨髓惡性腫瘤的治療費用不斷上漲
  • 市場機會
    • 強調個人化醫療方法
    • 全球臨床試驗數量增加
  • 市場挑戰
    • 與骨髓惡性腫瘤相關的副作用

波特五力：駕馭骨髓惡性腫瘤檢測市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解骨髓惡性腫瘤檢測市場的外部影響

外部宏觀環境因素在塑造骨髓惡性腫瘤檢測市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解骨髓惡性腫瘤檢測市場競爭狀況

骨髓惡性腫瘤檢測市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣骨髓惡性腫瘤檢測市場供應商的績效評估

FPNV定位矩陣是評估骨髓惡性腫瘤檢測市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪骨髓惡性腫瘤檢測市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對骨髓惡性腫瘤檢測市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告提供了涵蓋關鍵重點領域的市場全面分析：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 人口老化和骨髓惡性腫瘤發生率增加
      • 早期診斷和治療的趨勢
      • 免疫療法和標靶藥物介紹
    • 抑制因素
      • 造血系統惡性治療費用上漲
    • 機會
      • 強調個人化醫療方法
      • 世界各地的臨床試驗不斷增加
    • 任務
      • 與造血系統惡性相關的副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章骨髓惡性腫瘤檢測市場：依產品

  • 消耗品
  • 服務
  • 檢測套組

第7章骨髓惡性腫瘤檢測市場：依技術分類

  • 螢光原位雜合反應
  • 免疫組織化學
  • 次世代定序
  • 聚合酵素鏈鎖反應

第8章骨髓惡性腫瘤檢測市場：依疾病類型

  • 白血病
  • 淋巴瘤
  • 多發性骨髓瘤
  • 骨髓發育不良症候群
  • 骨髓增生性腫瘤

第9章骨髓惡性腫瘤檢測市場：依最終用戶分類

  • 醫院
  • 調查機構
  • 專科診所

第10章 美洲骨髓惡性腫瘤檢測市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太骨髓惡性腫瘤檢測市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲骨髓惡性腫瘤檢測市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Adaptive Biotechnologies
  • Agilent Technologies, Inc.
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd.
  • HORIBA, Ltd.
  • ICON PLC
  • Illumina, Inc.
  • Invitae Corporation
  • Invivoscribe, Inc.
  • Laboratory Corporation of America Holdings
  • Leica Biosystems Nussloch GmbH
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • Nikon Instruments
  • Ortho Clinical Diagnostics
  • PerkinElmer Corporation
  • QIAGEN NV
  • Siemens AG
  • Sysmex Corporation
  • Sysmex Inostics Inc.
Product Code: MRR-2E76C3E47FC1

The Hematologic Malignancies Testing Market was valued at USD 3.35 billion in 2023, expected to reach USD 3.60 billion in 2024, and is projected to grow at a CAGR of 7.82%, to USD 5.69 billion by 2030.

The scope of Hematologic Malignancies Testing encompasses a range of diagnostic and monitoring tools designed to identify and characterize blood cancers, including leukemia, lymphoma, and myeloma. These tests are crucial in determining specific cancer types, assessing the disease's progression, and formulating personalized treatment plans, making them indispensable to both healthcare providers and patients. Market application spans clinical diagnostics, research, and personalized medicine, with end-users primarily being hospitals, laboratories, and research institutions. A key growth factor driving the market is the increasing prevalence of hematologic cancers coupled with advancements in genetic and molecular testing techniques. Moreover, a growing focus on personalized medicine and early disease detection bolsters the demand for these tests. Recent technological advancements such as next-generation sequencing and PCR-based methods offer potential opportunities to cater to the rising demand for precise and rapid diagnostics. Companies looking to capitalize on these opportunities should invest in R&D to improve testing accuracy and reduce costs, thereby enhancing accessibility. However, limitations such as high costs of advanced testing equipment, regulatory hurdles, and a need for specialized personnel pose challenges to market growth. Additionally, disparities in healthcare infrastructure and access in emerging markets further impede widespread adoption. Innovation in this space can stem from the development of more cost-effective and portable testing solutions, enhancing point-of-care diagnostics, and integrating AI and machine learning for better data interpretation. The market's evolutionary nature is reflected in its commitment to bridging technological advancements with clinical applications. Businesses should focus on strategic collaborations and continuous innovation in molecular diagnostics, genetic testing, and biosensors to stay competitive, meeting the demand for accuracy and efficiency in cancer diagnostics.

KEY MARKET STATISTICS
Base Year [2023] USD 3.35 billion
Estimated Year [2024] USD 3.60 billion
Forecast Year [2030] USD 5.69 billion
CAGR (%) 7.82%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hematologic Malignancies Testing Market

The Hematologic Malignancies Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising aging population and incidences of hematologic malignancies
    • Inclination toward early diagnosis and treatment
    • Adoption of immunotherapies and targeted drugs
  • Market Restraints
    • High cost of hematologic malignancy treatment
  • Market Opportunities
    • Emphasis on personalized medicine approaches
    • Increasing number of clinical trials globally
  • Market Challenges
    • Adverse effects associated with hematologic malignancies

Porter's Five Forces: A Strategic Tool for Navigating the Hematologic Malignancies Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hematologic Malignancies Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hematologic Malignancies Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hematologic Malignancies Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hematologic Malignancies Testing Market

A detailed market share analysis in the Hematologic Malignancies Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hematologic Malignancies Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hematologic Malignancies Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hematologic Malignancies Testing Market

A strategic analysis of the Hematologic Malignancies Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hematologic Malignancies Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adaptive Biotechnologies, Agilent Technologies, Inc., Beckman Coulter, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., HORIBA, Ltd., ICON PLC, Illumina, Inc., Invitae Corporation, Invivoscribe, Inc., Laboratory Corporation of America Holdings, Leica Biosystems Nussloch GmbH, Myriad Genetics, Inc., Natera, Inc., Nikon Instruments, Ortho Clinical Diagnostics, PerkinElmer Corporation, QIAGEN N.V., Siemens AG, Sysmex Corporation, and Sysmex Inostics Inc..

Market Segmentation & Coverage

This research report categorizes the Hematologic Malignancies Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Consumables, Services, and Testing Kits.
  • Based on Technology, market is studied across Fluorescence In Situ Hybridization, Immunohistochemistry, Next-Generation Sequencing, and Polymerase Chain Reaction.
  • Based on Disease Type, market is studied across Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndrome, and Myeloproliferative Neoplasms.
  • Based on End-Users, market is studied across Hospitals, Research Institutions, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising aging population and incidences of hematologic malignancies
      • 5.1.1.2. Inclination toward early diagnosis and treatment
      • 5.1.1.3. Adoption of immunotherapies and targeted drugs
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of hematologic malignancy treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Emphasis on personalized medicine approaches
      • 5.1.3.2. Increasing number of clinical trials globally
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse effects associated with hematologic malignancies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Hematologic Malignancies Testing Market, by Product

  • 6.1. Introduction
  • 6.2. Consumables
  • 6.3. Services
  • 6.4. Testing Kits

7. Hematologic Malignancies Testing Market, by Technology

  • 7.1. Introduction
  • 7.2. Fluorescence In Situ Hybridization
  • 7.3. Immunohistochemistry
  • 7.4. Next-Generation Sequencing
  • 7.5. Polymerase Chain Reaction

8. Hematologic Malignancies Testing Market, by Disease Type

  • 8.1. Introduction
  • 8.2. Leukemia
  • 8.3. Lymphoma
  • 8.4. Multiple Myeloma
  • 8.5. Myelodysplastic Syndrome
  • 8.6. Myeloproliferative Neoplasms

9. Hematologic Malignancies Testing Market, by End-Users

  • 9.1. Introduction
  • 9.2. Hospitals
  • 9.3. Research Institutions
  • 9.4. Specialty Clinics

10. Americas Hematologic Malignancies Testing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Hematologic Malignancies Testing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Hematologic Malignancies Testing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Adaptive Biotechnologies
  • 3. Agilent Technologies, Inc.
  • 4. Beckman Coulter, Inc.
  • 5. Becton, Dickinson and Company
  • 6. Bio-Rad Laboratories, Inc.
  • 7. F. Hoffmann-La Roche Ltd.
  • 8. HORIBA, Ltd.
  • 9. ICON PLC
  • 10. Illumina, Inc.
  • 11. Invitae Corporation
  • 12. Invivoscribe, Inc.
  • 13. Laboratory Corporation of America Holdings
  • 14. Leica Biosystems Nussloch GmbH
  • 15. Myriad Genetics, Inc.
  • 16. Natera, Inc.
  • 17. Nikon Instruments
  • 18. Ortho Clinical Diagnostics
  • 19. PerkinElmer Corporation
  • 20. QIAGEN N.V.
  • 21. Siemens AG
  • 22. Sysmex Corporation
  • 23. Sysmex Inostics Inc.

LIST OF FIGURES

  • FIGURE 1. HEMATOLOGIC MALIGNANCIES TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. HEMATOLOGIC MALIGNANCIES TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. HEMATOLOGIC MALIGNANCIES TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HEMATOLOGIC MALIGNANCIES TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HEMATOLOGIC MALIGNANCIES TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TESTING KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MYELODYSPLASTIC SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MYELOPROLIFERATIVE NEOPLASMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 194. HEMATOLOGIC MALIGNANCIES TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 195. HEMATOLOGIC MALIGNANCIES TESTING MARKET, FPNV POSITIONING MATRIX, 2023